{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=19", "query": { "condition": "Advanced/Metastatic", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 3814, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T10:00:59.569Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05898399", "title": "Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "ART6043", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artios Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2023-06-30", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 7, "location_summary": "Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05898399" }, { "nct_id": "NCT01643499", "title": "Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of Unknown Primary", "Adult Primary Cholangiocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Duct Cell Adenocarcinoma of the Pancreas", "Intestinal Adenocarcinoma of the Stomach", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Carcinoma of Unknown Primary", "Metastatic Extrahepatic Bile Duct Cancer", "Mixed Adenocarcinoma of the Stomach", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Newly Diagnosed Carcinoma of Unknown Primary", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage III Pancreatic Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Rectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colon Cancer", "Stage IVA Gallbladder Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Gallbladder Cancer", "Stage IVB Rectal Cancer", "Unresectable Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2012-03-26", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 2, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643499" }, { "nct_id": "NCT02868632", "title": "Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-08-07", "completion_date": "2019-03-04", "has_results": false, "last_update_posted_date": "2019-04-05", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • New York, New York • The Bronx, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02868632" }, { "nct_id": "NCT03590054", "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage III Cutaneous Melanoma", "Stage IV Cutaneous Melanoma", "Locally Advanced Melanoma", "Locally Advanced Solid Neoplasm", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Non-Small Cell Lung Carcinoma", "Stage IB Lung Cancer AJCC v7", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Abexinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-08-20", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590054" }, { "nct_id": "NCT01375829", "title": "Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-06-27", "completion_date": "2027-03-19", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375829" }, { "nct_id": "NCT03937219", "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 855, "start_date": "2019-06-25", "completion_date": "2027-01-31", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 30, "location_summary": "La Jolla, California • Orange, California • Boca Raton, Florida + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03937219" }, { "nct_id": "NCT02266745", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "CRPC", "mCRPC", "Metastatic Castrate-resistant Prostate Cancer", "PT-112", "Prostatic Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms", "Neoplasms by Site" ], "interventions": [ { "name": "PT-112 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Promontory Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 109, "start_date": "2014-07", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02266745" }, { "nct_id": "NCT00371345", "title": "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastasis" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dasatinib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2006-12", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 7, "location_summary": "San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371345" }, { "nct_id": "NCT02109653", "title": "Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "LGX818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-06", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2020-11-13", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109653" }, { "nct_id": "NCT00052169", "title": "Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "ZD1839 in combination with docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2003-01", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2007-12-18", "last_synced_at": "2026-10-28T10:00:59.569Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052169" } ] }